Results 101 to 110 of about 225,446 (206)

Treatment of ophthalmopathy in the course of Graves’ disease

Journal of Education, Health and Sport, 2019
: Introduction: Graves’ disease is an autoimmune disease in which the TSH receptor (TSHR) is an autoantigen. Its stimulation by antibodies inhibiting thyrotropin binding causes increased secretion of free thyroid hormones and consequently symptoms of ...
Magdalena Woźniak, Ewa Tywanek, Grzegorz Rudzki, Joanna Świrska, Agnieszka Zwolak, Robert Jan Łuczyk   +5 more
doaj  

Immunomodulators in Graves' ophthalmopathy: a systematic review. [PDF]

Front Endocrinol (Lausanne)
Yeung A, Siddiqui MS, Mirtorabi N, Ahmed UN, Watts E, Sharma N, Kumari R, Boelaert K, Muzaffar J, Nieto H.   +9 more
europepmc   +1 more source

Visual Field and Graves Ophthalmopathy

, 2015
Whether primary or secondary to thyroid disease, Graves\u27 ophthalmopathy is surprising by its evolution despite correct treatment. Transformation to acute mode may occur very quickly.
Sabine Defoort-Dhellemmes; Jean-Philippe Woillez; Virginie Rufin
core  

Multiparametric MRI quantitative metrics for grading and staging graves' ophthalmopathy. [PDF]

BMC Med Imaging
Wu S, Yang L, Cai Y, Liang J, Wen J, Huang H, Yu S.   +6 more
europepmc   +1 more source

Epigenetic Modulation of Thyroid-Stimulating Hormone Receptor Expression in Orbital Fibroblasts From Graves' Ophthalmopathy: Target for Treatment. [PDF]

Invest Ophthalmol Vis Sci
Chompoowong R, Phankeaw P, Suwannavong A, Visamol S, Pitikiadtikun S, Saonanon P, Pruksakorn V, Potita P, Palaga T, Virakul S.   +9 more
europepmc   +1 more source

Correction: Extraocular muscle index as a novel indicator of inflammatory condition in graves' ophthalmopathy patients. [PDF]

Front Endocrinol (Lausanne)
Wu F, Huang J, Wang M, Qian Z, Wang Y, Fang W.   +5 more
europepmc   +1 more source

Euthyroid Graves' Ophthalmopathy With Negative Antibodies (EGONA): A Comprehensive Case-Based Review. [PDF]

Cureus
Bonny M, Wehbe M, Zaydan R, Alsadi M, Hakim L, Abu Alhasan J, Abu Helwa RS.   +6 more
europepmc   +1 more source

New-Onset Graves' Ophthalmopathy After Treatment with Pembrolizumab: A Case Report and a Review of the Literature. [PDF]

Diagnostics (Basel)
Pan M, Zhou X, Wu Y.
europepmc   +1 more source

Clinical value of dual-energy CT parameters combined with morphological features in predicting graves' ophthalmopathy. [PDF]

BMC Med Imaging
Ma Z, Shi T, Li W, Lu X, Yuan L, Zhang Y, Niu Y, Liu D.   +7 more
europepmc   +1 more source

Immunopathogenesis of Graves\u27 Ophthalmopathy

, 1984
Clinical Background. Course of Ophthalmopathy. This may occur at any time in relation to thyrotoxicosis and myoxedema. May improve, worsen, or not change with thyrotoxicosis management, and its uncertain relationship to medical, radioactive iodine, and ...
Robert C. Sergott
core